Margaret Dugan Sells 1,531 Shares of Schrödinger, Inc. (NASDAQ:SDGR) Stock

Schrödinger, Inc. (NASDAQ:SDGR) insider Margaret Dugan sold 1,531 shares of the company’s stock in a transaction dated Tuesday, October 15th. The stock was sold at an average price of $17.78, for a total value of $27,221.18. Following the completion of the transaction, the insider now directly owns 13,469 shares of the company’s stock, valued at approximately $239,478.82. The trade was a 0.00 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Schrödinger Trading Down 1.8 %

Shares of SDGR opened at $17.59 on Friday. The firm’s fifty day simple moving average is $19.33 and its two-hundred day simple moving average is $21.37. Schrödinger, Inc. has a 12 month low of $16.67 and a 12 month high of $38.00. The stock has a market capitalization of $1.28 billion, a P/E ratio of -6.56 and a beta of 1.50.

Schrödinger (NASDAQ:SDGR) last released its earnings results on Wednesday, July 31st. The company reported ($0.74) EPS for the quarter, topping the consensus estimate of ($0.85) by $0.11. The business had revenue of $47.33 million during the quarter, compared to analysts’ expectations of $40.19 million. Schrödinger had a negative return on equity of 38.38% and a negative net margin of 100.42%. As a group, research analysts predict that Schrödinger, Inc. will post -2.19 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several analysts have recently weighed in on SDGR shares. Leerink Partners initiated coverage on Schrödinger in a report on Tuesday, July 2nd. They set an “outperform” rating and a $29.00 price target on the stock. Morgan Stanley decreased their price target on shares of Schrödinger from $43.00 to $30.00 and set an “equal weight” rating for the company in a research report on Wednesday, August 21st. Leerink Partnrs upgraded shares of Schrödinger to a “strong-buy” rating in a report on Tuesday, July 2nd. BMO Capital Markets reduced their price objective on shares of Schrödinger from $30.00 to $25.00 and set an “outperform” rating on the stock in a research note on Thursday. Finally, KeyCorp lowered their target price on Schrödinger from $30.00 to $25.00 and set an “overweight” rating for the company in a research report on Thursday, July 11th. Three analysts have rated the stock with a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $32.60.

Institutional Trading of Schrödinger

Several large investors have recently modified their holdings of the stock. Nisa Investment Advisors LLC boosted its stake in Schrödinger by 145.3% during the second quarter. Nisa Investment Advisors LLC now owns 1,413 shares of the company’s stock worth $27,000 after acquiring an additional 837 shares in the last quarter. GAMMA Investing LLC grew its stake in shares of Schrödinger by 49.5% in the 2nd quarter. GAMMA Investing LLC now owns 2,124 shares of the company’s stock valued at $41,000 after buying an additional 703 shares during the period. nVerses Capital LLC bought a new stake in Schrödinger in the 2nd quarter valued at about $66,000. PNC Financial Services Group Inc. raised its stake in Schrödinger by 186.7% during the 4th quarter. PNC Financial Services Group Inc. now owns 2,127 shares of the company’s stock worth $76,000 after buying an additional 1,385 shares during the period. Finally, Quest Partners LLC raised its stake in Schrödinger by 1,005.6% during the 2nd quarter. Quest Partners LLC now owns 4,555 shares of the company’s stock worth $88,000 after buying an additional 4,143 shares during the period. Institutional investors and hedge funds own 79.05% of the company’s stock.

Schrödinger Company Profile

Schrödinger, Inc, together with its subsidiaries, develops physics-based computational platform that enables discovery of novel molecules for drug development and materials applications. The company operates in two segments, Software and Drug Discovery. The Software segment is focused on licensing its software to transform molecular discovery for life sciences and materials science industries.